With regard to, for example, infectious diseases domain, which is not included in the four critical areas of 2015, will non-critical projects be suspended?
A7. We do not mean that. The four critical domains are areas in which we deploy research and development resources with priority in preparation for 2015, and this certainly is an aspect of our research and development strategy. In addition, we, of course, have been considering how we can develop and maintain the domains over which Daiichi Pharmaceutical and Sankyo have had a significant presence to date.